Overview

Low-Dose Naltrexone For ME/CFS: Dose-Finding

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-01

Target enrollment:

Participant gender:

Summary

This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the entire U.S.

Phase:

PHASE2

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Naltrexone